Modern gene therapies raise hopes of combating many diseases until now considered terminal. Today, however, the methods are expensive and carry a risk of severe complications. Modifications to ribonucleic acid mRNA may offer safer and more effective gene drug alternatives. Clinical trials of the first new-generation anti-cancer vaccine will begin later this year.